{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:58Z","timestamp":1786982758798,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40264-022-01168-1","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T15:03:50Z","timestamp":1647443030000},"page":"345-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and Breastfeeding"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3352-8480","authenticated-orcid":false,"given":"Sigal","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6742-943X","authenticated-orcid":false,"given":"Mikhail","family":"Zeygarnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"issue":"10","key":"1168_CR1","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/wnl.0000000000007035","volume":"92","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029\u201340. https:\/\/doi.org\/10.1212\/wnl.0000000000007035.","journal-title":"Neurology"},{"issue":"4","key":"1168_CR2","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.1016\/s2214-109x(18)30029-9","volume":"6","author":"J Bearak","year":"2018","unstructured":"Bearak J, Popinchalk A, Alkema L, Sedgh G. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. Lancet Glob Health. 2018;6(4):e380\u20139. https:\/\/doi.org\/10.1016\/s2214-109x(18)30029-9.","journal-title":"Lancet Glob Health"},{"key":"1168_CR3","unstructured":"US Department of Health and Human Services. Office of the Surgeon General. The Surgeon General's call to action to support breastfeeding. Washington, DC, 2011. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK52682\/pdf\/Bookshelf_NBK52682.pdf. Accessed 1 Aug 2021."},{"issue":"6","key":"1168_CR4","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1097\/aog.0000000000000541","volume":"124","author":"R Bove","year":"2014","unstructured":"Bove R, Alwan S, Friedman JM, Hellwig K, Houtchens M, Koren G, et al. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol. 2014;124(6):1157\u201368. https:\/\/doi.org\/10.1097\/aog.0000000000000541.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"1168_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1001\/jamaneurol.2019.4173","volume":"77","author":"KM Krysko","year":"2020","unstructured":"Krysko KM, Rutatangwa A, Graves J, Lazar A, Waubant E. Association between breastfeeding and postpartum multiple sclerosis relapses: a systematic review and meta-analysis. JAMA Neurol. 2020;77(3):327\u201338. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4173.","journal-title":"JAMA Neurol"},{"issue":"18","key":"1168_CR6","doi-asserted-by":"publisher","first-page":"e1939","DOI":"10.1212\/wnl.0000000000009374","volume":"94","author":"A Langer-Gould","year":"2020","unstructured":"Langer-Gould A, Smith JB, Albers KB, Xiang AH, Wu J, Kerezsi EH, et al. Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. Neurology. 2020;94(18):e1939\u201349. https:\/\/doi.org\/10.1212\/wnl.0000000000009374.","journal-title":"Neurology"},{"key":"1168_CR7","unstructured":"Teva Pharmaceuticals Ltd. Copaxone (glatiramer acetate) 20& 40 mg\/ml solution for injection in pre-filled syringe [summary of product characteristics]. 2022. Available from: http:\/\/www.hpra.ie\/homepage\/medicines\/medicines-information\/find-a-medicine\/results?query=Copaxone&field=. Accessed 10 Feb 2022."},{"key":"1168_CR8","unstructured":"Teva Pharmaceuticals. Copaxone (glatiramer acetate injection) [prescribing Information]. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/020622s110lbl.pdf. Accessed 1 Aug 2021."},{"key":"1168_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1471-2377-12-124","volume":"12","author":"M Giannini","year":"2012","unstructured":"Giannini M, Portaccio E, Ghezzi A, Hakiki B, Past\u00f2 L, Razzolini L, et al. Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 2012;12:124. https:\/\/doi.org\/10.1186\/1471-2377-12-124.","journal-title":"BMC Neurol"},{"issue":"5","key":"1168_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1756285612453192","volume":"5","author":"K Hellwig","year":"2012","unstructured":"Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord. 2012;5(5):247\u201353. https:\/\/doi.org\/10.1177\/1756285612453192.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"1168_CR11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1177\/1352458515623366","volume":"22","author":"S Herbstritt","year":"2016","unstructured":"Herbstritt S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, et al. Glatiramer acetate during early pregnancy: a prospective cohort study. Mult Scler. 2016;22(6):810\u20136. https:\/\/doi.org\/10.1177\/1352458515623366.","journal-title":"Mult Scler"},{"issue":"4","key":"1168_CR12","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/pds.4735","volume":"28","author":"SC MacDonald","year":"2019","unstructured":"MacDonald SC, McElrath TF, Hern\u00e1ndez-D\u00edaz S. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis. Pharmacoepidemiol Drug Saf. 2019;28(4):556\u201360. https:\/\/doi.org\/10.1002\/pds.4735.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1168_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.msard.2019.01.003","volume":"28","author":"AL Nguyen","year":"2019","unstructured":"Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, et al. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study. Mult Scler Relat Disord. 2019;28:235\u201343. https:\/\/doi.org\/10.1016\/j.msard.2019.01.003.","journal-title":"Mult Scler Relat Disord."},{"issue":"1","key":"1168_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7224\/1537-2073.2016-079","volume":"20","author":"M Sandberg-Wollheim","year":"2018","unstructured":"Sandberg-Wollheim M, Neudorfer O, Grinspan A, Weinstock-Guttman B, Haas J, Izquierdo G, et al. Pregnancy outcomes from the Branded Glatiramer Acetate Pregnancy Database. Int J MS Care. 2018;20(1):9\u201314. https:\/\/doi.org\/10.7224\/1537-2073.2016-079.","journal-title":"Int J MS Care."},{"key":"1168_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000757","author":"AI Ciplea","year":"2020","unstructured":"Ciplea AI, Langer-Gould A, Stahl A, Thiel S, Queisser-Wahrendorf A, Gold R, et al. Safety of potential breast milk exposure to IFN-\u03b2 or glatiramer acetate: one-year infant outcomes. Neurol Neuroimmunol Neuroinflamm. 2020. https:\/\/doi.org\/10.1212\/nxi.0000000000000757.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1168_CR16","unstructured":"European Medicines Agency (EMA). Guideline on Good Pharmacovigilance Practices (GVP): product- or population-specific considerations III: pregnant and breastfeeding women. 2019. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-good-pharmacovigilance-practices-product-population-specific-considerations-iii_en.pdf. Accessed 3 Aug 2021."},{"key":"1168_CR17","unstructured":"University of California San Francisco (UCSF) Health. Pregnancy: the three trimesters. 2020. Available from: https:\/\/www.ucsfhealth.org\/conditions\/pregnancy\/trimesters. Accessed 3 Aug 2021."},{"key":"1168_CR18","unstructured":"Centers for Disease Control and Prevention (CDC). Metropolitan Atlanta Congenital Defects Program (MACDP). 2021. Available from: https:\/\/www.cdc.gov\/ncbddd\/birthdefects\/macdp.html. Accessed 29 Aug 2021."},{"key":"1168_CR19","unstructured":"European Surveillance of Congenital Anomalies (EUROCAT). Guide 1.4 and reference documents. 2018. Available from: https:\/\/eu-rd-platform.jrc.ec.europa.eu\/sites\/default\/files\/Full_Guide_1_4_version_28_DEC2018.pdf. Accessed 29 Aug 2021."},{"issue":"9","key":"1168_CR20","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/bdra.20842","volume":"91","author":"LB Holmes","year":"2011","unstructured":"Holmes LB, Westgate MN. Inclusion and exclusion criteria for malformations in newborn infants exposed to potential teratogens. Birth Defects Res A Clin Mol Teratol. 2011;91(9):807\u201312. https:\/\/doi.org\/10.1002\/bdra.20842.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"1","key":"1168_CR21","first-page":"1","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","unstructured":"Centers for Disease Control and Prevention. Update on overall prevalence of major birth defects: Atlanta, Georgia, 1978\u20132005. MMWR Morb Mortal Wkly Rep. 2008;57(1):1\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1168_CR22","unstructured":"European Network for Surveillance of Congenital Anomalies (EUROCAT). Prevalence charts and tables. Available from: https:\/\/eu-rd-platform.jrc.ec.europa.eu\/eurocat\/eurocat-data\/prevalence_en. Accessed 28 Jan 2022."},{"issue":"5","key":"1168_CR23","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/art.27358","volume":"62","author":"CD Chambers","year":"2010","unstructured":"Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, Lopez-Jimenez J, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 2010;62(5):1494\u2013503. https:\/\/doi.org\/10.1002\/art.27358.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1168_CR24","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/art.38368","volume":"66","author":"C Weber-Schoendorfer","year":"2014","unstructured":"Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Shechtman S, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66(5):1101\u201310. https:\/\/doi.org\/10.1002\/art.38368.","journal-title":"Arthritis Rheumatol"},{"key":"1168_CR25","unstructured":"EUROCAT. European network of population-based registries for the epidemiological surveillance of congenital anomalies. Available from: https:\/\/eu-rd-platform.jrc.ec.europa.eu\/eurocat_en. Accessed 28 Jan 2022."},{"key":"1168_CR26","unstructured":"Robert Koch Institute. Reference percentiles for anthropometric measures and blood pressure based on the German Health Interview and Examination Survey for Children and Adolescents 2003\u20132006 (KiGGS). Berlin, Germany. 2016. Available from: https:\/\/www.rki.de\/EN\/Content\/Health_Monitoring\/Health_Reporting\/GBEDownloadsB\/KiGGS_referenzperzentile.pdf?__blob=publicationFile. Accessed 19 Aug 2021."},{"key":"1168_CR27","unstructured":"MSD and the MSD Manuals. WHO infant weight for length percentiles (<24 months). Merck Sharp & Dohme Corp. 2022. Available from: https:\/\/www.msdmanuals.com\/professional\/multimedia\/clinical-calculator\/who-infant-weight-for-length-percentiles-24-months. Accessed 28 Jan 2022."},{"issue":"1","key":"1168_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/ppe.12417","volume":"32","author":"LM Rossen","year":"2018","unstructured":"Rossen LM, Ahrens KA, Branum AM. Trends in risk of pregnancy loss among US women, 1990\u20132011. Paediatr Perinat Epidemiol. 2018;32(1):19\u201329. https:\/\/doi.org\/10.1111\/ppe.12417.","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"29","key":"1168_CR29","first-page":"1","volume":"47","author":"SJ Ventura","year":"1999","unstructured":"Ventura SJ, Mosher WD, Curtin SC, Abma JC, Henshaw S. Highlights of trends in pregnancies and pregnancy rates by outcome: estimates for the United States, 1976\u201396. Natl Vital Stat Rep. 1999;47(29):1\u20139.","journal-title":"Natl Vital Stat Rep"},{"issue":"2","key":"1168_CR30","first-page":"1","volume":"70","author":"JA Martin","year":"2021","unstructured":"Martin JA, Hamilton BE, Osterman MJK, Driscoll AK. Births: final data for 2019. Natl Vital Stat Rep. 2021;70(2):1\u201351.","journal-title":"Natl Vital Stat Rep"},{"issue":"4","key":"1168_CR31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10995-016-2155-1","volume":"21","author":"AM Branum","year":"2017","unstructured":"Branum AM, Ahrens KA. Trends in timing of pregnancy awareness among US women. Matern Child Health J. 2017;21(4):715\u201326. https:\/\/doi.org\/10.1007\/s10995-016-2155-1.","journal-title":"Matern Child Health J"},{"key":"1168_CR32","volume-title":"Half life","author":"J Hallare","year":"2022","unstructured":"Hallare J, Gerriets V. Half life. Treasure Island: StatPearls Publishing LLC; 2022."},{"issue":"4","key":"1168_CR33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/bdra.20658","volume":"88","author":"C Bower","year":"2010","unstructured":"Bower C, Rudy E, Callaghan A, Quick J, Nassar N. Age at diagnosis of birth defects. Birth Defects Res A Clin Mol Teratol. 2010;88(4):251\u20135. https:\/\/doi.org\/10.1002\/bdra.20658.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"9","key":"1168_CR34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/bdra.23534","volume":"106","author":"CS Gibson","year":"2016","unstructured":"Gibson CS, Scott H, Haan E, Scheil W. Age range for inclusion affects ascertainment by birth defects registers. Birth Defects Res A Clin Mol Teratol. 2016;106(9):761\u20136. https:\/\/doi.org\/10.1002\/bdra.23534.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"2","key":"1168_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/ene.13536","volume":"25","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018;25(2):215\u201337. https:\/\/doi.org\/10.1111\/ene.13536.","journal-title":"Eur J Neurol"},{"key":"1168_CR36","unstructured":"Ciplea A, Kurzeja A, Thiel S, Haben S, Alexander J, Adamus E, et al. Safety analysis of offspring breastfed by mothers on glatiramer acetate therapy for relapsing multiple sclerosis. Abstracts of the 7th Congress of the European Academy of Neurology, June 2021, Virtual Congress, Eur J Neurol, 2021, p. 201\u20132."},{"issue":"2 Suppl.","key":"1168_CR37","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/13524585211044667","volume":"27","author":"A Ciplea","year":"2021","unstructured":"Ciplea A, Kurzeja A, Thiel S, Haben S, Alexander J, Adamus E, et al. Offspring outcomes among breastfeeding mothers on glatiramer acetate treatment for relapsing multiple sclerosis: subgroup analysis. Mult Scler J. 2021;27(2 Suppl.):243\u20134. https:\/\/doi.org\/10.1177\/13524585211044667.","journal-title":"Mult Scler J"},{"issue":"2","key":"1168_CR38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/practneurol-2018-002060","volume":"19","author":"R Dobson","year":"2019","unstructured":"Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: \u201cAssociation of British Neurologists\u201d guidelines. Pract Neurol. 2019;19(2):106\u201314. https:\/\/doi.org\/10.1136\/practneurol-2018-002060.","journal-title":"Pract Neurol"},{"key":"1168_CR39","unstructured":"Merck Europe B.V. Rebif 22 micrograms solution for injection in pre-filled syringe [summary of product characteristics]. 2021. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2021\/20211213154233\/anx_154233_en.pdf. Accessed 10 Feb 2022."},{"key":"1168_CR40","unstructured":"Bayer AG. Betaferon 250 microgram\/ml, powder and solvent for solution for injection [summary of product characteristics]. 2021. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2021\/20211022153456\/anx_153456_en.pdf. Accessed 10 Feb 2022."},{"issue":"10","key":"1168_CR41","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2015.1806","volume":"72","author":"K Hellwig","year":"2015","unstructured":"Hellwig K, Rockhoff M, Herbstritt S, Borisow N, Haghikia A, Elias-Hamp B, et al. Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses. JAMA Neurol. 2015;72(10):1132\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2015.1806.","journal-title":"JAMA Neurol"},{"issue":"10","key":"1168_CR42","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1517\/17425255.2013.811489","volume":"9","author":"S Messina","year":"2013","unstructured":"Messina S, Patti F. The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment. Expert Opin Drug Metab Toxicol. 2013;9(10):1349\u201359. https:\/\/doi.org\/10.1517\/17425255.2013.811489.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1168_CR43","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.reprotox.2019.01.006","volume":"84","author":"S Kaplan","year":"2019","unstructured":"Kaplan S, Shalit Y. Using patient support programs for pregnancy surveillance: current paradigm, emerging opportunity. Reprod Toxicol. 2019;84:122\u20134. https:\/\/doi.org\/10.1016\/j.reprotox.2019.01.006.","journal-title":"Reprod Toxicol"},{"key":"1168_CR44","unstructured":"Centers for Disease Control and Prevention (CDC). Breastfeeding report card. 2020. Available from: https:\/\/www.cdc.gov\/breastfeeding\/data\/reportcard.htm#:~:text=Although%20most%20infants%20born%20in,among%20infants%20born%20in%202016. Accessed 28 Jan 2022."},{"issue":"21","key":"1168_CR45","doi-asserted-by":"publisher","first-page":"769","DOI":"10.15585\/mmwr.mm7021a1","volume":"70","author":"KV Chiang","year":"2021","unstructured":"Chiang KV, Li R, Anstey EH, Perrine CG. Racial and ethnic disparities in breastfeeding initiation: United States, 2019. MMWR Morb Mortal Wkly Rep. 2021;70(21):769\u201374. https:\/\/doi.org\/10.15585\/mmwr.mm7021a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1168_CR46","unstructured":"UNICEF UK. The baby friendly initiative. Breastfeeding in the UK (Infant Feeding Survey). UNICEF. 2010. Available from: http:\/\/www.unicef.org.uk\/babyfriendly\/about\/breastfeeding-in-the-uk\/. Accessed 28 Jan 2022."},{"key":"1168_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00297-6","author":"L Lorefice","year":"2021","unstructured":"Lorefice L, Fronza M, Fenu G, Frau J, Coghe G, D\u2019Alterio MN, et al. Effects of pregnancy and breastfeeding on clinical outcomes and MRI measurements of women with multiple sclerosis: an exploratory real-world cohort study. Neurol Ther. 2021. https:\/\/doi.org\/10.1007\/s40120-021-00297-6.","journal-title":"Neurol Ther."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01168-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01168-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01168-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T13:08:38Z","timestamp":1650460118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01168-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1168"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01168-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"23 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This analysis was funded by Teva Pharmaceutical Industries Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sigal Kaplan, Mikhail Zeygarnik, and Tal Stern are employees of Teva Pharmaceutical Industries Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The analyses were conducted retrospectively as part of a regulatory commitment using de-identified patient data, and thus, were deemed exempt from ethics approval and informed consent was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The original contributions presented in the study are included in this published article and its supplementary information files.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SK: study supervision, analysis, interpretation of data, drafting of manuscript. MZ: study supervision, analysis, interpretation of data. TS: data acquisition, analysis, interpretation of data. All authors reviewed and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The views expressed in this article are those of the authors and do not necessarily reflect those of Teva Pharmaceutical Industries Ltd. and\/or its affiliates.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}